Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Guidance Mulls Uncertainty In Device Reviews

Executive Summary

New draft guidelines from US FDA offer a framework on how the agency will review device applications that include some uncertainty as to the benefits and risks of the technology.

You may also be interested in...



FDA Finalizes Guidance On Benefit-Risk Uncertainty

A new guidance document from the US agency attempts to make the process for weighing uncertainty in benefit-risk determinations more transparent and consistent.

Shuren: New Uncertainty Draft Guidance Looks Beyond p-Values

After years of talking about how to tackle uncertainty of benefit/risk in devices under review, US FDA has released a guidance on the issue. Medtech Insight caught up with FDA device center director Jeff Shuren at a meeting in Washington, DC, to talk about the guidance and what he hopes will come of it.

'Breakthrough' Blueprint: US FDA Draft Guideline Outlines Revised Expedited Development Program

The Breakthrough Devices Program is the established Expedited Access Pathway with some statutory updates, including the addition of 510(k)-pathway devices. But FDA also uses the congressionally-mandated draft guidelines to outline some new features in the program that are not in the statute, including a process for "breakthrough device sprint discussions."

Topics

UsernamePublicRestriction

Register

MT123242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel